Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AlloStim,Avelumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Merck Group
Deal Size : Undisclosed
Deal Type : Collaboration
Mirror Biologics, Merck KGaA Collaborate on Metastatic Colorectal Cancer
Details : The collaboration aims to conduct a Phase II to evaluate the combination of an experimental immunotherapy drug, AlloStim, and an immune checkpoint inhibitor, Bavencio avelumab from Merck.
Product Name : AlloStim
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
January 08, 2025
Lead Product(s) : AlloStim,Avelumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Merck Group
Deal Size : Undisclosed
Deal Type : Collaboration
Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer
Details : Allostim is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
August 16, 2024
Lead Product(s) : Allostim
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Immunovative (Thailand)
Deal Size : Inapplicable
Deal Type : Inapplicable
Immunotherapy for Advanced Liver Cancer
Details : Allostim is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 02, 2021
Lead Product(s) : Allostim
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Immunovative (Thailand)
Deal Size : Inapplicable
Deal Type : Inapplicable
Immunotherapy for Third Line Metastatic Colorectal Cancer
Details : Allostim is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
June 23, 2020
Lead Product(s) : Allostim
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Universal Anti-Viral Vaccine for Healthy Elderly Adults
Details : Allostim is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Virus Diseases.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
June 22, 2020
Lead Product(s) : Allostim
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Allovax is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 09, 2015
An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects
Details : Allovax is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 07, 2015
Details : Allostim is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 05, 2015
Lead Product(s) : Allostim
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Allostim is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
December 23, 2013
Lead Product(s) : Allostim
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Allovax is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Head and Neck Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 29, 2013
Reset All
